April 19, 2011

Partner John J. Molenda moderated the program “Industry Perspectives on the Biologics Act” at an event sponsored by The Federal Circuit Bar Association on April 19.  Dr. Molenda was joined by panelists: Susan Hart-White, Assistant General Counsel & Head of Regulatory Law, Privacy and Policy Group at sanofi-aventis, U.S.; Noreen Johnson, Vice President of Intellectual Property, Spinal and Biologics at Medtronic, Inc.; Nick Poulos, Associate Vice President, U.S. Patent Litigation at sanofi-aventis, U.S.; and Sean Ryder, Director of Legal at Glenmark Generics, Inc., USA.  Dr. Molenda moderated a discussion about the central importance of the Biologics Price Competition and Innovation Act of 2009 on the future of many industries.  He discussed key provisions of the Act and their wide-ranging implications to brand and generic pharmaceutical companies as well as medical device manufacturers. 

Dr. Molenda is a member of the Firm’s Litigation Department.  He is also a member of the Firm’s Intellectual Property, Appellate and Supreme Court, and Pharmaceutical, Biotech and Medical Devices Practices. In view of his background in pharmaceutical and biotech research, Dr. Molenda has acquired extensive experience in litigating patent cases in both of those fields.  With respect to pharmaceuticals, he has litigated numerous Hatch-Waxman and non-Hatch-Waxman cases on behalf of both brand and generic companies. With respect to biotechnology, he has represented clients litigating patents involving genetic engineering, molecular biology, and cell biology-related inventions. 

Please click here for event information.